Nivolumab is an immune checkpoint inhibitor proved to extend survival in patients with metastatic melanoma, non–small-cell lung cancer (NSCLC), and renal-cell carcinoma (RCC). When patients receive nivolumab combined with ipilimumab, they experience higher tumor response rates and increased progression-free survival. Patients receiving combined immunotherapeutic agents experience higher rates of immune-related adverse events compared with patients receiving monotherapy.
Overcoming HER2/ER Crosstalk: Neratinib Alone or in Combination with Fulvestrant in ER-Positive, HER2-Mutant Metastatic Breast Cancer in the Phase 2 SUMMIT Trial
The open-label, international, multicenter, multinational, phase 2 SUMMIT trial explored the efficacy and safety of neratinib monotherapy in patients with HER2-mutant metastatic breast cancer (MBC), and neratinib in combination with fulvestrant in patients with estrogen receptor (ER)-positive and HER2-positive MBC.
Mechanism of Action of Neratinib: An Irreversible Pan-HER Inhibitor in Late-Stage Clinical Development
Trastuzumab is a monoclonal antibody used for the treatment of HER2-positive breast cancer. Despite the efficacy of trastuzumab in the adjuvant setting, 1 in 4 patients experience disease recurrence. Neratinib is a potent, irreversible, pan-HER tyrosine kinase inhibitor that can combat mechanisms of disease escape and recurrence experienced with other HER2-targeted therapies.
Beth Faiman discusses the difficulty of keeping abreast of all the new multiple myeloma treatments and how she personally stays up to date on all of the information.
Beth Faiman reflects on the considerations involved with managing patients who have experienced multiple myeloma relapses.
Beth Faiman sees daratumumab as a game changer for patients with multiple myeloma.
Beth Faiman reviews the steps she takes upon introducing patients to daratumumab.
Beth Faiman gets questions from her patients about daratumumab on an almost daily basis. Find out what their most asked questions are.
Patients with newly diagnosed multiple myeloma have different needs than pateints relapsed/refractory disease, and Beth Faiman addresses what some of these needs are.
Beth Faiman explains how she identfies side effects that her patients are experiencing in order to open the lines of communication to better address other issues the patient may not be aware of.
Page 3 of 42
Results 21 - 30 of 412
Results 21 - 30 of 412